UBS Group
STOK icon

UBS Group’s Stoke Therapeutics STOK Stock Holding History

UBS Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.78M Buy
207,112
+48,808
+31% +$1.57M ﹤0.01% 3858
2026
Q1 		$5.15M Sell
158,304
-11,409
-7% -$374K ﹤0.01% 4057
2025
Q4 		$5.39M Sell
169,713
-136,324
-45% -$4.1M ﹤0.01% 3954
2025
Q3 		$7.19M Sell
306,037
-46,678
-13% -$800K ﹤0.01% 3651
2025
Q2 		$4M Buy
352,715
+180,884
+105% +$1.72M ﹤0.01% 4103
2025
Q1 		$1.14M Sell
171,831
-6,013
-3% -$56.1K ﹤0.01% 5170
2024
Q4 		$1.96M Buy
177,844
+99,532
+127% +$1.22M ﹤0.01% 4732
2024
Q3 		$962K Sell
78,312
-39,942
-34% -$566K ﹤0.01% 4687
2024
Q2 		$1.6M Buy
118,254
+78,839
+200% +$1.06M ﹤0.01% 3990
2024
Q1 		$532K Buy
39,415
+9,642
+32% +$58.4K ﹤0.01% 5159
2023
Q4 		$157K Buy
29,773
+9,498
+47% +$40.6K ﹤0.01% 5923
2023
Q3 		$79.9K Sell
20,275
-2,806
-12% -$18.5K ﹤0.01% 5981
2023
Q2 		$245K Buy
23,081
+9,004
+64% +$95.8K ﹤0.01% 5351
2023
Q1 		$117K Sell
14,077
-661
-4% -$5.96K ﹤0.01% 5795
2022
Q4 		$136K Buy
14,738
+11,046
+299% +$115K ﹤0.01% 5806
2022
Q3 		$47K Buy
+3,692
New +$58.8K ﹤0.01% 6410
2022
Q2 		– Sell
-51,941
Closed -$1.09M – 10911
2022
Q1 		$1.09M Buy
51,941
+8,664
+20% +$173K ﹤0.01% 4005
2021
Q4 		$1.04M Buy
43,277
+10,464
+32% +$250K ﹤0.01% 4362
2021
Q3 		$835K Buy
32,813
+28,571
+674% +$797K ﹤0.01% 4342
2021
Q2 		$143K Sell
4,242
-11,073
-72% -$391K ﹤0.01% 5609
2021
Q1 		$595K Buy
+15,315
New +$872K ﹤0.01% 4738
2020
Q2 		– Sell
-4,380
Closed -$100K – 8339
2020
Q1 		$100K Sell
4,380
-4,769
-52% -$118K ﹤0.01% 5296
2019
Q4 		$259K Buy
9,149
+3,075
+51% +$77.3K ﹤0.01% 5414
2019
Q3 		$131K Buy
6,074
+4,554
+300% +$127K ﹤0.01% 5588
2019
Q2 		$44K Buy
+1,520
New +$40.8K ﹤0.01% 6036

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's STOK Position: Q2 2026 in Review

UBS Group increased its Stoke Therapeutics (STOK) stake by 31% in Q2 2026, buying an estimated $1.57M and bringing the position to 207,112 shares worth $6.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3858.

UBS Group first reported a position in STOK in Q2 2019 and has held it in 25 quarters since. The position peaked at $7.19M in Q3 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • UBS Group held 207,112 shares of Stoke Therapeutics worth $6.78M as of Q2 2026.
  • UBS Group bought 48,808 Stoke Therapeutics shares in Q2 2026, an estimated $1.57M.
  • Stoke Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3858 holding.
  • UBS Group first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • UBS Group's Stoke Therapeutics position peaked at $7.19M in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.